ALTSTATION.IO

Blackstone Inc. (BX) Stock Analysis

By Nova Skye | AltStation.io | Updated November 08, 2026

Price

$119.50

Change

-0.27%

Market Cap

$148.61B

Avg Volume

4.8M

Company Overview

Blackstone Inc. (BX) is an alternative asset manager based in New York that invests capital across private equity, real estate, hedge fund solutions, credit, and public markets. Founded in 1985, the firm operates in the Asset Management segment of the Financial Services sector, managing capital across North America, Europe, Asia, and Latin America. They sell investment strategies and fund management services to clients seeking exposure to private markets, while also providing capital markets services. The company targets businesses with enterprise values between $500 million and $5,000 million, deploying between $0.25 million and $900 million per transaction.

Blackstone operates as a heavyweight in alternative asset management, using massive cross-asset reach from commercial real estate to private credit as its main competitive edge. Their distinct strength lies in handling everything from seed-stage checks up to $900 million buyouts, alongside fund of funds equity commitments up to $300 million. The primary threat to their model stems from substantial exposure to non-investment grade corporate credit, distressed debt, and commercial real estate dislocations. Operating with a three-year investment period also creates constant deployment pressure against rival asset management firms competing for the same buyout and growth assets.

Blackstone is actively deploying capital across both high-growth modern sectors and physical infrastructure rather than narrowing its focus. The firm continues to push into specialized segments like renewable power generation, enterprise software, life sciences, and physical real estate development through subsidiaries like South City Projects. Rather than retreating from credit risk, their credit division remains aggressively committed to financing non-investment grade firms across senior debt, subordinated debt, and equity structures. Operating across North America, Europe, Asia, and Central America, the firm maintains an expansive multi-asset stance built to capture upside across both distressed corporate situations and stabilized income properties.

Key Financials

Market Cap

$148.61B

Revenue

$15.47B

EBITDA

N/A

Gross Margin

100.0%

Profit Margin

23.0%

Revenue Growth

-0.5%

Total Cash

$3.04B

Total Debt

$14.19B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

26.61

Forward P/E

16.20

Beta

1.53

52-Week High

$165.14

52-Week Low

$101.73

EPS

$4.49

50-Day Avg

$120.36

200-Day Avg

$123.21

Price/Book

10.81

Technical Analysis

BX trades at $119.50, 35% of the way from its $98.84 52-week low to its $158.60 high. The stock remains 24.65% below that high but is 20.91% above the low. Price is 4.39% above the 20-day moving average of $114.48, supported by 1.80% momentum over five trading days and 5.56% over 20 days. Near-term support sits at the 30-day low of $105.21. Near-term resistance is the 30-day high of $125.57.

Recent News and Developments

Blackstone closes €13 billion European direct-lending fund

Blackstone closed its fourth institutional European direct-lending fund with approximately €13 billion of investable capital, including anticipated leverage. The strategy targets middle- and upper-middle-market European borrowers. Source: Blackstone

Blackstone backs Boston Scientific heart pump with $455 million

Blackstone Life Sciences entered a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST temporary heart pump. It is the first development-funding partnership between the two companies. Source: Blackstone

Blackstone leads $3.1 billion LNG Canada investment

A Blackstone-led investor group agreed to pay $3.1 billion for a 49.9% non-controlling interest in a Mitsubishi subsidiary holding its LNG Canada stake. The planned Phase 2 expansion would double the terminal’s production capacity to 28 million tonnes per year. Source: Blackstone

Market Sentiment and Analyst Recommendations

Bull Case

BX has $15.47 billion in revenue and a $148.61 billion market cap, giving it the scale to pursue large opportunities across multiple asset classes. The new European direct-lending fund provides approximately €13 billion of investable capital and expands Blackstone’s exposure to middle- and upper-middle-market borrowers. Its $455 million collaboration with Boston Scientific adds a life-sciences growth opportunity tied to the VITALYST heart pump. The Blackstone-led $3.1 billion LNG Canada investment offers exposure to a planned expansion that would double production capacity to 28 million tonnes per year. Analysts remain constructive, with a buy recommendation from 22 analysts and an average target of $138.86. With BX at $119.50 and technical momentum positive over both five and 20 trading days, the bull case is that the recent recovery still has room to run.

Bear Case

Revenue growth is negative at -0.5%, which is the clearest fundamental weakness in the data. A P/E of 26.61 leaves little room for weak growth or disappointing investment performance. Total debt stands at $14.19 billion against only $3.04 billion in cash, creating a meaningful balance-sheet gap. Blackstone also completed a $1.1 billion debt offering carrying 5.650% and 5.900% interest rates, adding financing costs for general corporate purposes. The analyst target range starts at $118.00, below the current $119.50 price, so the most cautious analysts see no upside. The stock’s November volatility also matters: BX jumped 6.24% to $125.57 on November 4, then dropped 4.58% to $119.82 on November 5. My concern is simple: BX is priced at 26.61 times earnings while revenue is shrinking.

What to Watch

The first metric to watch next quarter is revenue growth, currently -0.5%; a return to positive growth would strengthen the thesis. Watch whether BX holds above its $114.48 20-day moving average and whether buyers can push it through $125.57 resistance. A break below $105.21 support would weaken the technical setup. Investors should track deployment of the approximately €13 billion European direct-lending fund and whether demand remains strong among its target borrowers. The $455 million Boston Scientific collaboration and $3.1 billion LNG Canada transaction are important execution tests for Blackstone’s ability to turn large commitments into returns. The $1.1 billion debt offering also puts financing costs in focus, particularly the 5.650% notes due in 2031 and 5.900% notes due in 2033. The clearest bullish confirmation would be positive revenue growth paired with a move above $125.57; negative growth and a break below $105.21 would argue the opposite.

Analyst Consensus

BUY

Based on 22 analyst opinions

Low Target

$118.00

Mean Target

$138.86

High Target

$169.00

Earnings and Financial Data

Sector

Financial Services

Industry

Asset Management

Employees

5,285

Earnings & Dividends

Next Earnings

Jan 28, 2027

EPS (Trailing)

$4.49

Dividend Yield

423.0%

Payout Ratio

111.2%

Frequently Asked Questions

Is BX a good stock to buy?

BX has a buy recommendation from 22 analysts and trades at $119.50 versus an average analyst target of $138.86. The takeaway is that analysts are bullish, but the -0.5% revenue growth remains a real concern.

What is BX’s price target?

The average analyst target is $138.86, with estimates ranging from $118.00 to $169.00. The takeaway is that the consensus target sits above the current $119.50 price, although the low estimate does not.

Is BX stock overvalued?

BX trades at a P/E of 26.61 while reported revenue growth is -0.5%. The takeaway is that the valuation demands stronger growth than the current revenue figure shows.

What are the support and resistance levels for BX?

Near-term support is $105.21, the 30-day low, while resistance is $125.57, the 30-day high. The takeaway is that these are the key levels defining the current trading range.

Does BX pay a dividend?

The provided data does not include a dividend amount or yield, so a dividend claim cannot be confirmed here. The takeaway is that investors should verify current dividend information separately before making an income-based decision.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated November 08, 2026.